Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.66 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.53 |
| ▸ | DRD4 | P21917 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739108 | 0.94 | ABCB1 (0.74) | ABCB1ABCG2DHCR7ABCC1 | |
| SCHEMBL8790054 | 0.90 | ABCB1 (0.71) | ABCB1ABCG2ABCC1 | |
| SCHEMBL8789531 | 0.86 | ABCB1 (0.81) | ABCB1ABCG2DHCR7 | |
| Hydrochloric Acid SCHEMBL10659282 | 0.85 | ABCB1 (0.80) | ABCB1ABCG2DHCR7 | |
| SCHEMBL14740471 | 0.84 | DHCR7 (0.73) | ABCB1ABCG2DHCR7ABCC1 | |
| SCHEMBL15295391 | 0.83 | ABCG2 (0.56) | ABCB1ABCG2DHCR7ABCC1TDP1 | |
| SCHEMBL14739770 | 0.83 | ABCB1 (0.56) | ABCB1ABCG2DHCR7ABCC1DRD3 | |
| SCHEMBL17664978 | 0.80 | ABCB1 (0.69) | ABCB1ABCG2DHCR7 | |
| SCHEMBL14740058 | 0.80 | ABCB1 (0.52) | ABCB1ABCG2DRD1DRD2 | |
| SCHEMBL31633306 | 0.80 | ABCB1 (0.52) | ABCB1ABCG2DRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589626-B1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | UNIV NAT TAIWAN (TW) | 2024-06-12 | — | — | EP | disclosed |
| US-8552028-B2 | 8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-10-08 | — | — | US | disclosed |
| US-20130059882-A1 | 8-Phenylisoquinolines And Pharmaceutical Composition Used In Treatment For Sepsis | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059882-A1 | 8-Phenylisoquinolines And Pharmaceutical Composition Used In Treatment For Sepsis | CXCL8, THPO, IL18 | ABCB1 275/4885ABCG2 1385/4885DHCR7 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.